Clinical Trials Browser

Interventional × Ramucirumab × Clear all

NCT06203600 2026-03-17

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Phase 2/3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT06445972 2026-03-16

MK-3475-06D

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT03686488 2026-03-02

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase 2 Completed

23 enrolled 12 charts

Gastrointestinal

Stomach Neoplasms

NCT06996782 2026-02-24

ALTAIR

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05980000 2026-02-06

Rambro2

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06007937 2026-02-05

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT07098338 2026-02-05

LIBRA

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Solid Cancer

NCT03008278 2026-02-03

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Phase 1/2 Completed

51 enrolled 20 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT04340882 2026-01-30

DoceRamPem

Phase 2 Active not recruiting

Lung Neoplasms

NCT03798626 2026-01-27

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1 Completed

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT06031688 2026-01-23

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03650764 2025-12-30

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT04145349 2025-12-08

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Phase 1/2 Active not recruiting

30 enrolled 16 charts

Sarcoma, Desmoplastic Small Round Cell Tumor

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06251973 2025-12-02

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Phase 1 Terminated

88 enrolled 18 charts

Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

NCT04205968 2025-11-05

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Phase 2 Recruiting

Metastatic Small Intestinal Adenocarcinoma

NCT03694002 2025-10-30

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

21 enrolled 17 charts

Thymoma

NCT02597036 2025-10-23

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Phase 1 Terminated

62 enrolled 25 charts

Other solid neoplasm

Solid Tumors

NCT03909334 2025-10-20

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05071053 2025-08-22

CARMEN-GC01

Phase 2 Terminated

35 enrolled 14 charts

Gastrointestinal

Adenocarcinoma Gastric

NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Phase 2 Active not recruiting

309 enrolled 22 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04069273 2025-07-31

SEQUEL

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04120454 2025-07-11

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

6 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05894824 2025-07-11

T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase 1/2 Recruiting

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT02678182 2025-06-10

PLATFORM

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma of the Oesophagus

NCT04394624 2025-06-06

CARMEN-LC04

Phase 2 Terminated

31 enrolled 22 charts

Non-small Cell Lung Cancer Metastatic

NCT05633602 2025-05-28

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05311176 2025-05-11

nextHERIZON

Phase 2 Terminated

7 enrolled 8 charts

Gastrointestinal

Stomach Neoplasms

NCT03560973 2025-03-13

RAMES

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma

NCT05062980 2025-02-20

Acclaim-2

Phase 1/2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02795858 2025-02-19

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Phase 2 Completed

43 enrolled 11 charts

Carcinoid Tumor

NCT04499924 2025-01-22

MOUNTAINEER-02

Phase 2/3 Completed

17 enrolled 23 charts

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT02581215 2025-01-01

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

Phase 2 Completed

84 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03081143 2024-12-12

RAMIRIS

Phase 2/3 Active not recruiting

Gastrointestinal

Advanced Gastric or EGJ Cancer

NCT02791334 2024-09-27

PACT

Phase 1 Completed

BreastDermatologicGastrointestinal

Breast Neoplasms, Melanoma, Pancreatic Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT06564298 2024-08-28

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT06542731 2024-08-07

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Phase 1 Completed

175 enrolled 23 charts

GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03760822 2024-07-08

SOCRATE

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT03921671 2024-05-29

RELEVENT

Phase 2 Unknown

Neoplasm Metastasis, Thymoma

NCT03502746 2024-05-14

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Phase 2 Terminated

34 enrolled 11 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04660760 2024-04-01

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Phase 2 Recruiting

Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8